Alpine Immune Sciences, Inc. (ALPN)
| Market Cap | 294.56M |
| Revenue (ttm) | 4.58M |
| Net Income (ttm) | -27.74M |
| Shares Out | 22.28M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $11.55 |
| Previous Close | $12.71 |
| Change ($) | -1.16 |
| Change (%) | -9.13% |
| Day's Open | 12.75 |
| Day's Range | 11.39 - 12.99 |
| Day's Volume | 171,021 |
| 52-Week Range | 2.15 - 15.96 |
Although micro-cap stocks don't perform well during an economic downturn, they outperform the market during periods of recovery. Here are 7 stocks to invest in as we head toward a new normal.
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Executive Leadership Addition and Promotion
Alpine Immune Sciences is a stellar growth bio-stock that is reaching a point of growth inflection. Back in June last year, Alpine secured a highly favorable partnership with AbbVie.
Innovation paid off big for investors.
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors
Alpine (ALPN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Participate in Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Participate in Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q3 2020 Results - Earnings Call Transcript
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Third Quarter 2020 Financial Results and Provide Corporate Update
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2020 Results - Earnings Call Transcript
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces $60 Million Private Placement
As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences, Inc. (ALPN).
Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.
Shortly after markets jumped in response to June's jobs report, gains were erased as a surge in coronavirus cases was reported across the country. This puts a damper on the economy's recovery.
Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.
Alpine Immune Sciences stock rose more than 10% Friday after the Seattle-based biotech company inked a $60 million licensing deal with pharmaceutical giant AbbVie for its lupus drug.
Shares of the micro-cap, clinical-stage immune therapy company Alpine Immune Sciences Inc (NASDAQ: ALPN) were advancing strongly Thursday.
Alpine Immune Sciences Inc. (NASDAQ: ALPN) shares doubled on Thursday after the company announced a license agreement with AbbVie Inc.
As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences.
Alpine Immune Sciences has been struggling lately, but the selling pressure may be coming to an end soon.
Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q4 2019 Results - Earnings Call Transcript
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Total earnings for the S&P 500 companies are estimated to drop 4% from the same period last year, which would be the first quarterly decline since 2016.
As of late, it has definitely been a great time to be an investor in Nivalis Therapeutics.
About ALPN
Alpine Immune Sciences focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the tre... [Read more...]
| Industry Biotechnology | |
| CEO Charles Scoggin | Employees 53 |
| Stock Exchange NASDAQ | Ticker Symbol ALPN |
Financial Performance
In 2019, ALPN's revenue was $1.74 million, an increase of 146.81% compared to the previous year's $705,000. Losses were -$41.85 million, 14.7% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for ALPN stock is "Strong Buy." The 12-month stock price forecast is 21.40, which is an increase of 85.28% from the latest price.